Quantcast

Latest Biostrophin Stories

2010-10-15 07:00:00

SOUTH PLAINFIELD, N.J., Oct. 15 /PRNewswire/ -- PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions...

2010-08-09 12:14:00

Dr. Jerry Mendell Leading Follistatin Gene Therapy MIDDLETOWN, Ohio, Aug. 9 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), will award a $600,000 grant to Nationwide Children's Hospital in Columbus, Ohio to conduct clinical testing of a promising gene therapy technique for muscle disease. (Logo:...

2010-06-10 09:00:00

Dr. Dongsheng Duan and Nicholas Dobes to Receive Grants MIDDLETOWN, Ohio, June 10 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today that PPMD will be funding two critical, promising research initiatives in Duchenne. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO)...

2010-03-16 16:10:00

By administering a chemical called a 'molecular band-aid,' U of M researchers were able to prevent heart injury in dystrophic canines MINNEAPOLIS -- Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients "“ a fatal and most common form of muscular dystrophy in children. The chemical, which Medical School scientists have termed a "molecular band-aid," seeks out tiny...

2010-01-06 01:20:00

AMSTERDAM, January 6 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD). The credit is granted by SenterNovem, an agency of the Dutch Ministry of Economic affairs. "We are delighted to receive this credit for DMD,...

2009-11-11 00:00:00

AMSTERDAM, November 11 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has successfully treated Duchenne muscular dystrophy (DMD) in an animal model with its proprietary gene therapy. The proof of concept studies were performed in collaboration with the group of Professor Irene Bozzoni (University of Rome, La Sapienza, Italy) and demonstrated effectiveness in the heart as well as in skeletal...

2009-10-13 00:00:00

AMSTERDAM, October 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy. Orphan Drug Designation for Duchenne muscular dystrophy (DMD) entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-080 if this...

2009-05-27 08:29:28

Researchers at the University of Minnesota Medical School have discovered a new therapy that shows potential to treat people with Duchenne muscular dystrophy, a fatal disease and the most common form of muscular dystrophy in children.In the mouse model, researchers were able to substitute for the missing protein "“ dystrophin, which forms a key part of the framework that holds muscle tissue together "“ that results in the disease, effectively repairing weakened muscle...

2009-04-30 15:00:00

Former New York Giants Jim Burt and Bart Oates Help Raise Money and Awareness for Duchenne Muscular Dystrophy FORT LEE, N.J., April 30 /PRNewswire-USNewswire/ -- Pat Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD) announced today that former New York Giant stars Jim Burt and Bart Oates will join hundreds of guests for the 1st Annual Pour for a Cure, supporting PPMD, at the Hyatt Regency in New Brunswick, New Jersey on May 8, 2009. More than just a wine tasting...

2009-04-20 09:37:29

U.S. scientists say they've conducted the first gene therapy trial for a form of muscular dystrophy that disables by weakening hip and shoulder muscles. Researchers from the University of Florida, Nationwide Children's Hospital in Columbus, Ohio, and Ohio State University said they safely transferred a gene to produce a protein necessary for healthy muscle fiber growth into three teenagers with limb-girdle muscular dystrophy. We think this is an important milestone in establishing the...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related